Kallman syndrome pathophysiology: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Kallman syndrome}} {{CMG}} ==Overview== ==References== {{reflist|2}} {{WH}} {{WS}} Category:Disease Category:Endocrinology Category:Genetic disorders...")
 
Line 4: Line 4:


==Overview==
==Overview==
==Pathophysiology==
Under normal conditions, GnRH travels from the hypothalamus to the [[pituitary gland]] via the [[hypophyseal portal system]], where it triggers production and release of [[gonadotropin]]s ([[luteinizing hormone|LH]] and [[follicle stimulating hormone|FSH]]) from the [[gonadotrope]]s.  When GnRH is low, the pituitary does not create the normal amount of gonadotropins. The gonadotropins normally increase the production of [[sex steroid|gonadal steroids]], so when they are low, these steroids will be low as well.
In Kallmann syndrome, the GnRH neurons do not migrate properly from the olfactory [[placode]] to the hypothalamus during development.  The olfactory bulbs also fail to form or have hypoplasia, leading to anosmia or hyposmia.
Kallmann syndrome can be inherited as an X-linked recessive trait, in which case there is a defect in the [[KAL1 gene|KAL1]] gene, which maps to chromosome Xp22.3.<ref name="pmid12062015">{{cite journal |author=MacColl G, Bouloux P, Quinton R |title=Kallmann syndrome: adhesion, afferents, and anosmia |journal=Neuron |volume=34 |issue=5 |pages=675–8 |year=2002 |pmid=12062015 |doi=10.1016/S0896-6273(02)00720-1}}</ref> KAL encodes a neural cell adhesion molecule, [[anosmin-1]]. Anosmin-1 is normally expressed in the [[brain]], [[face|facial]] [[mesenchyme]], [[mesonephros]] and [[metanephros]]. It is required to promote migration of [[GnRH]] neurons into the [[hypothalamus]]. It also allows migration of olfactory neurons from the [[olfactory bulbs]] to the hypothalamus.
An autosomal dominant gene on chromosome 8 {8p12} (KAL-2 or FGFR-1 (fibroblast growth factor receptor 1)) is thought to cause about 10% of cases. There is some recent evidence to suggest a degree of linkage between the KAL-1 and FGFR-1 genes.
An additional autosomal cause of Kallmann syndrome has been reported<ref>Dode C, et al. Kallmann syndrome: mutations in the genes encoding prokineticin-2 and prokineticin receptor-2. PLoS Genet.2: e175, 2006.</ref> by a mutations in the prokineticin receptor-2 gene (PROKR2)(KAL-3) at position 20p13 and its ligand prokineticin 2 (PROK2)(KAL-4) at position 3p21.1. It was noted that mutations in these genes brought about various degrees of olfactory and reproductive dysfunction, but not the other symptoms seen in KAL-1 and KAL-2 forms of Kallmann Syndrome. The authors of the paper suggested that up to 30% of all Kallmann Syndrome cases can be linked to known genetic mutations.


==References==
==References==

Revision as of 16:21, 19 September 2012

Kallman syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Kallman Syndrome from other Diseases

Epidemiology and Demographics

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Social Impact

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Kallman syndrome pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Kallman syndrome pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Kallman syndrome pathophysiology

CDC on Kallman syndrome pathophysiology

Kallman syndrome pathophysiology in the news

Blogs on Kallman syndrome pathophysiology

Directions to Hospitals Treating Kallman syndrome

Risk calculators and risk factors for Kallman syndrome pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Pathophysiology

Under normal conditions, GnRH travels from the hypothalamus to the pituitary gland via the hypophyseal portal system, where it triggers production and release of gonadotropins (LH and FSH) from the gonadotropes. When GnRH is low, the pituitary does not create the normal amount of gonadotropins. The gonadotropins normally increase the production of gonadal steroids, so when they are low, these steroids will be low as well.

In Kallmann syndrome, the GnRH neurons do not migrate properly from the olfactory placode to the hypothalamus during development. The olfactory bulbs also fail to form or have hypoplasia, leading to anosmia or hyposmia.

Kallmann syndrome can be inherited as an X-linked recessive trait, in which case there is a defect in the KAL1 gene, which maps to chromosome Xp22.3.[1] KAL encodes a neural cell adhesion molecule, anosmin-1. Anosmin-1 is normally expressed in the brain, facial mesenchyme, mesonephros and metanephros. It is required to promote migration of GnRH neurons into the hypothalamus. It also allows migration of olfactory neurons from the olfactory bulbs to the hypothalamus.

An autosomal dominant gene on chromosome 8 {8p12} (KAL-2 or FGFR-1 (fibroblast growth factor receptor 1)) is thought to cause about 10% of cases. There is some recent evidence to suggest a degree of linkage between the KAL-1 and FGFR-1 genes.

An additional autosomal cause of Kallmann syndrome has been reported[2] by a mutations in the prokineticin receptor-2 gene (PROKR2)(KAL-3) at position 20p13 and its ligand prokineticin 2 (PROK2)(KAL-4) at position 3p21.1. It was noted that mutations in these genes brought about various degrees of olfactory and reproductive dysfunction, but not the other symptoms seen in KAL-1 and KAL-2 forms of Kallmann Syndrome. The authors of the paper suggested that up to 30% of all Kallmann Syndrome cases can be linked to known genetic mutations.

References

  1. MacColl G, Bouloux P, Quinton R (2002). "Kallmann syndrome: adhesion, afferents, and anosmia". Neuron. 34 (5): 675–8. doi:10.1016/S0896-6273(02)00720-1. PMID 12062015.
  2. Dode C, et al. Kallmann syndrome: mutations in the genes encoding prokineticin-2 and prokineticin receptor-2. PLoS Genet.2: e175, 2006.

Template:WH Template:WS